

Bill & Melinda Gates Foundation commits \$100M in response to 2019-nCoV

07 February 2020 | News

The foundation will provide up to \$100 million to improve detection, isolation and treatment efforts



The Bill & Melinda Gates Foundation has announced that it will immediately commit up to \$100 million for the global response to the 2019 novel coronavirus (2019-nCoV). The funding will help strengthen detection, isolation and treatment efforts; protect at-risk populations; and develop vaccines, treatments and diagnostics. The new funding is inclusive of \$10 million the foundation committed to the outbreak in late January.

The foundation will immediately commit up to \$20 million to accelerate the detection, isolation and treatment of people diagnosed with the virus with the goal of interrupting transmission and containing the disease.

This funding will be directed to multilateral organizations such as WHO and the U.S. Centers for Disease Control and Prevention. Support will also be directed to national public health authorities in China and other countries that have reported confirmed cases. Current national-level partners include the National Health Commission of China and the Chinese Center for Disease Control and Prevention.

The foundation will provide up to \$20 million to help public health authorities in sub-Saharan Africa and South Asia strengthen their emergency operations centers, implement effective disease surveillance efforts and improve their capacity to safely isolate and treat confirmed cases.

The foundation will use its R&D funding to help global partners, such as the Coalition for Epidemic Preparedness Innovations, identify and prioritize research needs, address gaps in the R&D landscape, incentivize product development by biotechnology and pharmaceutical companies and ensure that resulting products are safe, effective and made widely available. This effort will include support already underway for Chinese public- and private-sector research partners focused on the discovery, development and testing of candidate vaccines, treatments and diagnostics.